CF
CSTL icon

Corebridge Financial’s Castle Biosciences CSTL Stock Holding History

Corebridge Financial’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,866
Closed -$258K – 677
2025
Q1 		$258K Buy
12,866
+6
+0% +$149 ﹤0.01% 1920
2024
Q4 		$343K Sell
12,860
-972
-7% -$29.6K ﹤0.01% 1871
2024
Q3 		$394K Sell
13,832
-85
-0.6% -$2.16K ﹤0.01% 1854
2024
Q2 		$303K Buy
+13,917
New +$310K ﹤0.01% 1962

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Corebridge Financial's CSTL Position: Q2 2025 in Review

Corebridge Financial sold out of Castle Biosciences (CSTL) in Q2 2025, closing a stake of 12,866 shares — an estimated $258K sold.

Corebridge Financial first reported a position in CSTL in Q2 2024 and held it in 4 quarters. The position peaked at $394K in Q3 2024. 152 funds tracked by Wall St. Rank hold CSTL as of Q2 2025.

  • Corebridge Financial reported no remaining Castle Biosciences position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 12,866 Castle Biosciences shares in Q2 2025, an estimated $258K.
  • Corebridge Financial first reported a position in Castle Biosciences in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Castle Biosciences position peaked at $394K in Q3 2024.
  • 152 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.